BR112014020365B1 - Inibidores de pirazolopirimidinila de enzima de ativação de ubiquitina - Google Patents

Inibidores de pirazolopirimidinila de enzima de ativação de ubiquitina Download PDF

Info

Publication number
BR112014020365B1
BR112014020365B1 BR112014020365-2A BR112014020365A BR112014020365B1 BR 112014020365 B1 BR112014020365 B1 BR 112014020365B1 BR 112014020365 A BR112014020365 A BR 112014020365A BR 112014020365 B1 BR112014020365 B1 BR 112014020365B1
Authority
BR
Brazil
Prior art keywords
pyrimidin
pyrazolo
methyl
rac
ylamino
Prior art date
Application number
BR112014020365-2A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014020365A2 (pt
Inventor
Roushan Afroze
Indu T. Bharathan
Jeffrey P. Ciavarri
Paul E. Fleming
Jeffrey L. Gaulin
Mario Girard
Steven P. Langston
Francois R. Soucy
Tzu-Tshin Wong
Yingchun Ye
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of BR112014020365A2 publication Critical patent/BR112014020365A2/pt
Publication of BR112014020365B1 publication Critical patent/BR112014020365B1/pt

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR112014020365-2A 2012-02-17 2013-02-14 Inibidores de pirazolopirimidinila de enzima de ativação de ubiquitina BR112014020365B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261600070P 2012-02-17 2012-02-17
US61/600,070 2012-02-17
PCT/US2013/026113 WO2013123169A1 (en) 2012-02-17 2013-02-14 Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme

Publications (2)

Publication Number Publication Date
BR112014020365A2 BR112014020365A2 (pt) 2020-12-22
BR112014020365B1 true BR112014020365B1 (pt) 2023-02-23

Family

ID=48982730

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014020365-2A BR112014020365B1 (pt) 2012-02-17 2013-02-14 Inibidores de pirazolopirimidinila de enzima de ativação de ubiquitina

Country Status (30)

Country Link
US (4) US9290500B2 (https=)
EP (3) EP2814791A4 (https=)
JP (1) JP6122877B2 (https=)
KR (1) KR20140123104A (https=)
CN (1) CN104136399B (https=)
AR (1) AR092797A1 (https=)
BR (1) BR112014020365B1 (https=)
CA (1) CA2864672C (https=)
CL (1) CL2014002181A1 (https=)
CO (1) CO7071135A2 (https=)
CR (1) CR20140380A (https=)
DO (1) DOP2014000187A (https=)
EA (1) EA035020B1 (https=)
EC (1) ECSP14019113A (https=)
ES (1) ES2739150T3 (https=)
GE (1) GEP201706687B (https=)
HK (1) HK1201817A1 (https=)
IL (1) IL234016A0 (https=)
MA (1) MA35932B1 (https=)
MX (1) MX352963B (https=)
NZ (1) NZ628969A (https=)
PE (1) PE20142244A1 (https=)
PH (1) PH12014501832A1 (https=)
SG (2) SG10201606581RA (https=)
TN (1) TN2014000351A1 (https=)
TW (1) TWI593688B (https=)
UA (1) UA116534C2 (https=)
UY (1) UY34629A (https=)
WO (1) WO2013123169A1 (https=)
ZA (1) ZA201406103B (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
EP2814791A4 (en) 2012-02-17 2015-08-19 Millennium Pharm Inc PYRAZOLOPYRIMIDINYL INHIBITORS OF ACTIVATION ENZYME OF UBIQUITIN
EP2879681A4 (en) 2012-08-03 2015-12-23 Millennium Pharm Inc INDOINDUBSTITUTED PYRROLOPYRIMIDINYL HIBITORS OF UBA6
JP6378759B2 (ja) 2013-07-02 2018-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｓｕｍｏ活性化酵素阻害剤として有用なヘテロアリール化合物
SG11201610476VA (en) 2014-07-01 2017-01-27 Millennium Pharm Inc Heteroaryl compounds useful as inhibitors of sumo activating enzyme
JP6697453B2 (ja) * 2014-10-29 2020-05-20 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ユビキチン活性化酵素阻害物質及び放射線の投与
WO2016069392A1 (en) 2014-10-29 2016-05-06 Millennium Pharmaceuticals, Inc. Administration of ubiquitin-activating enzyme inhibitor and chemotherapeutic agents
AU2019370200B2 (en) 2018-10-30 2024-12-19 Kronos Bio, Inc. Compounds, compositions, and methods for modulating CDK9 activity
WO2022253188A1 (en) * 2021-05-31 2022-12-08 Impact Therapeutics (Shanghai) , Inc Nitrogen-containing fused heteroaromatic bicyclic compounds as usp1 inhibitors and the use thereof
WO2023021498A1 (en) * 2021-08-16 2023-02-23 Moya Bio Ltd. Fused azole and furan based nucleoside analogs and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003073989A2 (en) 2002-02-28 2003-09-12 Biota, Inc. Nucleoside 5'-monophosphate mimics and their prodrugs
US7196092B2 (en) 2002-09-04 2007-03-27 Schering Corporation N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors
US7563798B2 (en) 2002-09-04 2009-07-21 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
MY137843A (en) 2002-09-04 2009-03-31 Schering Corp Pyrazolopyrimidines as cyclin dependent kinase inhibitors
CA2497444C (en) 2002-09-04 2010-11-30 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US20070179161A1 (en) 2003-03-31 2007-08-02 Vernalis (Cambridge) Limited. Pyrazolopyrimidine compounds and their use in medicine
JP2005008581A (ja) * 2003-06-20 2005-01-13 Kissei Pharmaceut Co Ltd 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
US20050130974A1 (en) 2003-10-17 2005-06-16 Rigel Pharmaceuticals, Inc. Benzothiazole compositions and their use as ubiquitin ligase inhibitors
WO2006002284A1 (en) 2004-06-22 2006-01-05 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
RS52458B (sr) 2005-02-04 2013-02-28 Millennium Pharmaceuticals Inc. Inhibitori e1 aktivirajućih enzima
TWI333953B (en) 2005-10-06 2010-12-01 Schering Corp Pyrazolopyrimidines as protein kinase inhibitors
EA024006B1 (ru) 2006-02-02 2016-08-31 Миллениум Фармасьютикалз, Инк. Ингибиторы е1 активирующих ферментов
EP1992008A1 (en) * 2006-02-28 2008-11-19 Sez Ag Device and method for liquid treating disc-like articles
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
ZA200900670B (en) * 2006-08-08 2010-04-28 Millennium Pharm Inc Heteroaryl compounds useful as inhititors of E1 activating enzymes
JP5539864B2 (ja) 2007-06-12 2014-07-02 アカオゲン，インコーポレーテッド 抗菌剤
EP2178880B1 (en) 2007-08-02 2017-10-04 Millennium Pharmaceuticals, Inc. Process for the synthesis of e1 activating enzyme inhibitors
US9216983B2 (en) 2007-12-21 2015-12-22 Board Of Regents, University Of Texas System Dihydroorotate dehydrogenase inhibitors with selective anti-malarial activity
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
EP2430026A1 (en) 2009-05-14 2012-03-21 Millennium Pharmaceuticals, Inc. Hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate
MX2012010115A (es) 2010-03-01 2013-02-26 Gtx Inc Compuestos para el tratamiento de cancer.
US20120077814A1 (en) 2010-09-10 2012-03-29 Zhong Wang Sulfonamide, sulfamate, and sulfamothioate derivatives
JP6038150B2 (ja) 2011-08-24 2016-12-07 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｎｅｄｄ８活性化酵素阻害剤
EP2814791A4 (en) 2012-02-17 2015-08-19 Millennium Pharm Inc PYRAZOLOPYRIMIDINYL INHIBITORS OF ACTIVATION ENZYME OF UBIQUITIN
EP2879681A4 (en) 2012-08-03 2015-12-23 Millennium Pharm Inc INDOINDUBSTITUTED PYRROLOPYRIMIDINYL HIBITORS OF UBA6
JP6378759B2 (ja) 2013-07-02 2018-08-22 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｓｕｍｏ活性化酵素阻害剤として有用なヘテロアリール化合物
SG11201610476VA (en) 2014-07-01 2017-01-27 Millennium Pharm Inc Heteroaryl compounds useful as inhibitors of sumo activating enzyme

Also Published As

Publication number Publication date
MX352963B (es) 2017-12-15
CO7071135A2 (es) 2014-09-30
DOP2014000187A (es) 2014-10-15
EP3173413A1 (en) 2017-05-31
CN104136399B (zh) 2018-08-07
JP6122877B2 (ja) 2017-04-26
ECSP14019113A (es) 2015-09-30
EP2814791A4 (en) 2015-08-19
CL2014002181A1 (es) 2014-12-12
EP3536692A1 (en) 2019-09-11
NZ628969A (en) 2017-03-31
US9290500B2 (en) 2016-03-22
EA035020B1 (ru) 2020-04-17
AR092797A1 (es) 2015-05-06
MX2014009944A (es) 2014-11-10
SG10201606581RA (en) 2016-09-29
BR112014020365A2 (pt) 2020-12-22
TWI593688B (zh) 2017-08-01
HK1201817A1 (en) 2015-09-11
PH12014501832A1 (en) 2014-11-17
JP2015508775A (ja) 2015-03-23
US20170217968A1 (en) 2017-08-03
EA201400831A1 (ru) 2014-12-30
ZA201406103B (en) 2017-11-29
WO2013123169A1 (en) 2013-08-22
US20130217682A1 (en) 2013-08-22
EP3536692B1 (en) 2021-04-07
GEP201706687B (en) 2017-06-26
PE20142244A1 (es) 2015-01-07
US20160244455A1 (en) 2016-08-25
EP3173413B1 (en) 2019-05-01
TW201345909A (zh) 2013-11-16
CR20140380A (es) 2014-10-28
EP2814791A1 (en) 2014-12-24
CN104136399A (zh) 2014-11-05
SG11201404757WA (en) 2014-09-26
CA2864672A1 (en) 2013-08-22
US9796725B2 (en) 2017-10-24
TN2014000351A1 (en) 2015-12-21
IL234016A0 (en) 2014-09-30
US9663525B2 (en) 2017-05-30
MA35932B1 (fr) 2014-12-01
CA2864672C (en) 2018-01-09
KR20140123104A (ko) 2014-10-21
UA116534C2 (uk) 2018-04-10
US20140088096A9 (en) 2014-03-27
UY34629A (es) 2013-09-02
US20170369499A1 (en) 2017-12-28
US10202389B2 (en) 2019-02-12
ES2739150T3 (es) 2020-01-29

Similar Documents

Publication Publication Date Title
EP3536692B1 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
TWI798635B (zh) 吡啶並嘧啶酮類化合物及其應用
EP3484871B1 (en) Piperidine derivatives as inhibitors of cyclin dependent kinase 7 (cdk7)
EP2382207B1 (en) Pi3k/mtor kinase inhibitors
JP2015508775A5 (https=)
WO2011041399A2 (en) Pi3k (delta) selective inhibitors
TW201018696A (en) Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
US9156853B2 (en) AKT inhibitor compounds for treatment of cancer
WO2013016999A1 (zh) 杂芳基并嘧啶类衍生物、其制备方法和用途
JP2024535867A (ja) 治療薬としてｎ－アリールピリミジン－２－アミン誘導体を有する化合物
TW202321237A (zh) Ｍａｐ４ｋ１抑制劑
HK1238244A1 (en) Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
WO2022070289A1 (ja) ピリミジン含有含窒素二環化合物

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/02/2013, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 13A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2866 DE 09-12-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.